Compare PSMT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSMT | BLCO |
|---|---|---|
| Founded | 1994 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.4B |
| IPO Year | 2005 | 2022 |
| Metric | PSMT | BLCO |
|---|---|---|
| Price | $188.39 | $16.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.45 |
| AVG Volume (30 Days) | 288.8K | ★ 359.4K |
| Earning Date | 04-08-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 5.47 | N/A |
| EPS | ★ 4.18 | N/A |
| Revenue | $4,066,093,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $12.29 | $8.65 |
| Revenue Next Year | $10.70 | $5.59 |
| P/E Ratio | $44.56 | ★ N/A |
| Revenue Growth | ★ 12.33 | 6.47 |
| 52 Week Low | $105.46 | $13.09 |
| 52 Week High | $199.84 | $18.92 |
| Indicator | PSMT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 54.48 |
| Support Level | $182.73 | $16.26 |
| Resistance Level | $199.84 | $16.64 |
| Average True Range (ATR) | 6.75 | 0.45 |
| MACD | -1.30 | -0.05 |
| Stochastic Oscillator | 35.65 | 52.80 |
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.